Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene Hugo description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX
Showing element 933 to 982 of 3228 in total
Value Type: Ranked
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
933\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BHLHB5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
basic helix-loop-helix domain containing, class b, 5; trinucleotide repeat containing 20. [source:refseq;acc:nm\_152414]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
159.165\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
164.951\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03635\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
934\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NOL6\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nucleolar rna-associated protein alpha isoform. [source:refseq;acc:nm\_022917]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
242.024\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
233.544\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03631\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
935\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
sirtuin 7; sir2-related protein type 7; sirtuin type 7; sirtuin (silent mating type information regulation 2, s.cerevisiae, homolog) 7; silent mating type information regulation 2, s.cerevisiae, homolog 7; sirtuin silent mating type information regulation 2 homolog 7 (s. cerevisiae). [source:refseq;acc:nm\_016538]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
232.473\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
224.372\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03611\vspace{3pt}}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
936\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
casein kinase ii beta chain (ck ii) (phosvitin) (g5a). [source:swissprot;acc:p13862]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
937\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SF3A3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
splicing factor 3a subunit 3 (spliceosome associated protein 61) (sap 61) (sf3a60). [source:swissprot;acc:q12874]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
220.246\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
212.618\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03588\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
938\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SF3A1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
splicing factor 3 subunit 1 (spliceosome associated protein 114) (sap 114) (sf3a120). [source:swissprot;acc:q15459]\vspace{3pt}}&&&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
939\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BRCA1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
breast cancer type 1 susceptibility protein. [source:swissprot;acc:p38398]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
216.501\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
224.27\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
940\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CAPNS1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
calcium-dependent protease, small subunit (calpain regulatory subunit) (calcium-activated neutral proteinase) (canp). [source:swissprot;acc:p04632]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.442\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.088\vspace{3pt}}&\multirow{6}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03586\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
941\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARID1A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
swi/snf-related, matrix-associated, actin-dependent regulator of chromatin subfamily f member 1 (swi-snf complex protein p270) (b120). [source:swissprot;acc:o14497]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.437\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.083\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
942\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GCA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
grancalcin. [source:swissprot;acc:p28676]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
212.442\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.088\vspace{3pt}}&\\\cline{1-3}\cline{5-5}
\parbox{\wcA}{\vspace{3pt}\noindent
943\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SRI\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
sorcin (22 kda protein) (cp-22) (v19). [source:swissprot;acc:p30626]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
205.087\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
944\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PDCD6\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
programmed cell death protein 6 (probable calcium-binding protein alg- 2). [source:swissprot;acc:o75340]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.437\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.083\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
945\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARID1B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
brg1-binding protein eld/osa1; eld (eyelid)/osa protein. [source:refseq;acc:nm\_020732]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.44\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.085\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
946\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
histone h4. [source:swissprot;acc:p02304]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
227.765\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
219.902\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03576\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
947\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SORBS2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
arg/abl-interacting protein 2 isoform 2; arg binding protein 2. [source:refseq;acc:nm\_021069]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.51\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.191\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03567\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
948\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TOM1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
target of myb protein 1. [source:swissprot;acc:o60784]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.254\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.824\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03541\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
949\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
huntingtin-associated protein-interacting protein (duo protein). [source:swissprot;acc:o60229]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.253\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.826\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0354\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
950\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ERCC5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dna-repair protein complementing xp-g cells (xeroderma pigmentosum group g complementing protein) (dna excision repair protein ercc-5). [source:swissprot;acc:p28715]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
252.873\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
261.821\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03539\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
951\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRIO\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
triple functional domain protein (ptprf interacting protein). [source:swissprot;acc:o75962]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.253\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.827\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
952\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TOM1L2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
target of myb1-like 2; target of myb1 (chicken) homolog-like 2. [source:refseq;acc:nm\_144678]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.252\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.83\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03537\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
953\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EXOSC10\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
polymyositis/scleroderma autoantigen 2 (autoantigen pm/scl 2) (polymyositis/scleroderma autoantigen 100 kda) (pm/scl-100) (p100 polymyositis-scleroderma overlap syndrome associated autoantigen). [source:swissprot;acc:q01780]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
198.494\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.466\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03512\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
954\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GSTZ1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
maleylacetoacetate isomerase (ec 5.2.1.2) (maai) (glutathione s- transferase zeta 1) (ec 2.5.1.18) (gstz1-1). [source:swissprot;acc:o43708]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
267.447\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
276.773\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03487\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
955\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MRPL27\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mitochondrial 60s ribosomal protein l27 (l27mt) (hspc250). [source:swissprot;acc:q9p0m9]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
231.163\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
239.205\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03479\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
956\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SORBS3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
vinexin (sh3-containing adaptor molecule-1) (scam-1). [source:swissprot;acc:o60504]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
211.812\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
204.732\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03458\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
957\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARAF\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
a-raf proto-oncogene serine/threonine-protein kinase (ec 2.7.1.-) (a-raf-1) (proto-oncogene pks). [source:swissprot;acc:p10398]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
129.913\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
134.399\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03453\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
958\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAF1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
raf proto-oncogene serine/threonine-protein kinase (ec 2.7.1.-) (raf-1) (c-raf). [source:swissprot;acc:p04049]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
129.921\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
134.406\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03452\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
959\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
guanine nucleotide-binding protein beta subunit-like protein 12.3 (p205) (receptor of activated protein kinase c 1) (rack1) (receptor for activated c kinase). [source:swissprot;acc:p25388]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
237.558\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
229.677\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03431\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
960\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ZRF1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
zuotin related factor-1 (m-phase phosphoprotein 11). [source:swissprot;acc:q99543]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
961\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPP2R5E\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, 56 kda regulatory subunit, epsilon isoform (pp2a, b subunit, b' epsilon isoform) (pp2a, b subunit, b56 epsilon isoform) (pp2a, b subunit, pr61 epsilon isoform) (pp2a, b subunit, r5 epsilon isoform). [source:swissprot;acc:q16537]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
130.066\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
134.527\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.0343\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
962\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CCNG2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cyclin g2. [source:swissprot;acc:q16589]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
963\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CCNG1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cyclin g1 (cyclin g). [source:swissprot;acc:p51959]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
964\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPP2R5A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
serine/threonine protein phosphatase 2a, 56 kda regulatory subunit, alpha isoform (pp2a, b subunit, b' alpha isoform) (pp2a, b subunit, b56 alpha isoform) (pp2a, b subunit, pr61 alpha isoform) (pp2a, b subunit, r5 alpha isoform). [source:swissprot;acc:q15172]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
965\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PARD6G\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
partitioning defective-6 homolog gamma (par-6 gamma) (par6d). [source:swissprot;acc:q9byg4]\vspace{3pt}}&\multirow{11}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
211.987\vspace{3pt}}}&\multirow{11}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
204.964\vspace{3pt}}}&\multirow{11}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03426\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
966\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TUB\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
tubby protein homolog. [source:swissprot;acc:p50607]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
967\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PRKCI\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein kinase c, iota type (ec 2.7.1.37) (npkc-iota) (atypical protein kinase c-lamda/iota) (apkc-lambda/iota). [source:swissprot;acc:p41743]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
968\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUMB\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
numb protein homolog (h-numb) (protein s171). [source:swissprot;acc:p49757]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
969\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TBC1D5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
tbc1 domain family member 5. [source:swissprot;acc:q92609]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
970\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TULP1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
tubby related protein 1 (tubby-like protein 1). [source:swissprot;acc:o00294]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
971\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VPS29\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
vacuolar protein sorting 29 (vesicle protein sorting 29) (hvps29) (mds007) (pep11) (dc7/dc15). [source:swissprot;acc:q9ubq0]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
972\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUMBL\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
numb-like protein (numb-r). [source:swissprot;acc:q9y6r0]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
973\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TULP3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
tubby related protein 3 (tubby-like protein 3). [source:swissprot;acc:o75386]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
974\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VPS35\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
vacuolar protein sorting 35 (vesicle protein sorting 35) (hvps35) (maternal-embryonic 3). [source:swissprot;acc:q96qk1]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
975\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PRKCZ\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein kinase c, zeta type (ec 2.7.1.37) (npkc-zeta). [source:swissprot;acc:q05513]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
976\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WDR36\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
t-cell activation wd repeat protein. [source:refseq;acc:nm\_139281]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
243.34\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
235.322\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03407\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
977\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PFDN5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
prefoldin subunit 5 (c-myc binding protein mm-1) (myc modulator 1). [source:swissprot;acc:q99471]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
228.953\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
221.421\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03402\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
978\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
prefoldin subunit 6 (protein ke2). [source:swissprot;acc:o15212]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
979\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BLOC1S1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
gcn5-like protein 1 (rt14 protein). [source:swissprot;acc:p78537]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
202.027\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
195.386\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03399\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
980\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BRAF\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
b-raf proto-oncogene serine/threonine-protein kinase (ec 2.7.1.-) (p94) (v-raf murine sarcoma viral oncogene homolog b1). [source:swissprot;acc:p15056]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
130.289\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
134.713\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03396\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
981\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EXOC3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
exocyst complex component sec6. [source:swissprot;acc:o60645]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.186\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
200.398\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03387\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
982\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CIRH1A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cirhin; testis expressed gene 292; cirrhosis, autosomal recessive 1a. [source:refseq;acc:nm\_032830]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
243.312\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
235.351\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03383\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the HGNC identifier if it exists

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/